The human epidermal growth factor receptor-2 (HER2) is overexpressed in about 30% of invasive breast cancers, comprising triple negative and HER-2+ breast cancers; thus, representing a promising cancer vaccine target. This evidence concerns the gene ERBB2 and invasive breast carcinoma.